Alembic Pharma is planning to launch over 20 products in the current financial year (FY24), with a focus on oral solids, injectables, and derma segments.
Alembic Pharma has reported a Q1 net profit of INR 121 crore, up from a net loss of INR 66 crore YoY, led by increased sales growth across its segments. The Indian branded business recorded a 9% YoY growth to INR 524 crore, while US generics saw 6% YoY growth to INR 354 crore.
Alembic Pharma Share Price: Find the latest news on Alembic Pharma Stock Price. Get all the information on Alembic Pharma with historic price charts for NSE / BSE. Experts & Broker view also get the Alembic Pharma Ltd. buy/sell tips detailed news, announcements, Forecasts, Analysts, Valuation, Earning forecasts, Estimates, Recommendations, Analysts Ratings, financial report, company information, annual report, balance sheet, profit & loss account, results and more.
Synopsis
Alembic Pharma is looking forward to high growth with API and RoW businesses reporting decent growth. Besides, new products in pipeline and company’s reasonable valuation as compared to its peers have made it a favourite of analysts.
Alembic Pharmaceuticals was able to report only muted results for the third quarter of 2020-21. Its consolidated revenues grew by only 9% y-o-y. Despite the growth in ex-sartans portfolio, the US revenues stagnated around $70 million due to price fall in sartans portfolio. Sartans are drugs used for high blood pressure and heart failure. Though its consolidated net profit jumped up 25% y-o-y, it was majorly because of a milestone payment
Synopsis
Alembic Pharma is looking forward to high growth with API and RoW businesses reporting decent growth. Besides, new products in pipeline and company’s reasonable valuation as compared to its peers have made it a favourite of analysts.
Alembic Pharmaceuticals was able to report only muted results for the third quarter of 2020-21. Its consolidated revenues grew by only 9% y-o-y. Despite the growth in ex-sartans portfolio, the US revenues stagnated around $70 million due to price fall in sartans portfolio. Sartans are drugs used for high blood pressure and heart failure. Though its consolidated net profit jumped up 25% y-o-y, it was majorly because of a milestone payment